BioSpace News Archive

Iovance Biotherapeutics, Inc. announced that on July 20, 2023, the Company approved the grant of inducement stock options covering an aggregate of 71,800 shares of Iovance’s common stock to 8 new non-executive employees.

Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its clinical trial application of 7MW3711 for advanced malignant solid tumor was approved by the National Medical Products Administration (NMPA).

Ilumed announced today that Marco Castillo has been appointed the new Chief Transformation Officer of the company, tasked with leading continued growth for the company’s operations in ten states.

Nashville Biosciences, a wholly owned subsidiary of Vanderbilt University Medical Center, has announced a partnership with five major pharmaceutical companies to form the Alliance for Genomic Discovery.

In a potential therapeutic breakthrough, investigators at The Feinstein Institutes for Medical Research have identified a type of white blood cell that can worsen inflammation in sepsis and opens up new avenues of research to treat the deadly condition.

T2 Biosystems, Inc. a leader in the rapid detection of sepsis-causing pathogens, announced that it issued inducement awards to fourteen new employees.

ViewRay, Inc. announced that on July 17, it received a letter from the Listing Qualifications Department of the Nasdaq Stock Market LLC.

Avidity Biosciences, Inc. announced that on July 20, 2023, the Human Capital Management Committee of Avidity’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 33,150 shares of its common stock and 16,575 restricted stock units to eleven new non-executive employees under the Avidity Biosciences, Inc.

Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA) today announced U.S. Food and Drug Administration (FDA) approval of YCANTH™ (cantharidin) topical solution for the treatment of molluscum contagiosum (molluscum) in adult and pediatric patients 2 years of age and older.

YS Biopharma Co., Ltd. (NASDAQ: YS) (“YS Biopharma” or the “Company”) today announced that it plans to release its financial results for the fiscal year ended March 31, 2023 after the U.S. market closes on Wednesday, July 26, 2023.